Axovant Sciences (AXON) Earns Hold Rating from Oppenheimer

Oppenheimer reaffirmed their hold rating on shares of Axovant Sciences (NASDAQ:AXON) in a research note issued to investors on Sunday, November 12th. Oppenheimer also issued estimates for Axovant Sciences’ Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.00) EPS, FY2020 earnings at ($1.54) EPS and FY2022 earnings at ($0.79) EPS.

A number of other equities analysts have also recently weighed in on the company. BidaskClub cut Axovant Sciences from a sell rating to a strong sell rating in a report on Friday, September 15th. Evercore ISI started coverage on Axovant Sciences in a report on Friday, September 8th. They set an outperform rating and a $30.00 price target for the company. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a strong-buy rating and set a $8.00 price target for the company in a report on Monday, October 9th. HC Wainwright reiterated a buy rating on shares of Axovant Sciences in a report on Thursday, October 19th. Finally, Chardan Capital reiterated a sell rating and set a $3.00 price target on shares of Axovant Sciences in a report on Saturday, September 23rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $14.13.

Shares of Axovant Sciences (NASDAQ AXON) traded down $0.12 during mid-day trading on Friday, hitting $5.40. The stock had a trading volume of 803,584 shares, compared to its average volume of 1,018,484. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its stake in Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after acquiring an additional 6,558,462 shares in the last quarter. Capital Research Global Investors lifted its stake in Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after acquiring an additional 619,226 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Axovant Sciences during the 2nd quarter worth about $47,854,000. OxFORD Asset Management LLP raised its position in Axovant Sciences by 842.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares in the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in Axovant Sciences in the 3rd quarter valued at about $4,471,000. 96.93% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://baseballnewssource.com/markets/axovant-sciences-axon-hold-rating-reiterated-at-oppenheimer-holdings-inc/1779389.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.